Reviewer’s report

Title: Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: A meta-analysis

Version: 0 Date: 11 Oct 2019

Reviewer: Peter Penson

Reviewer's report:

Thank you for submitting this interesting manuscript.

Title
-Please consider changing your title. The title asks a question, the answer to which is subjective. A systematic Review and Meta-Analysis should ask a very objective question based upon a PICO (Population, intervention, comparator, outcome) strategy. Please consider re framing your title to contain the elements of PICO, thereby forming an objective question. Of course, none of this precludes you using the discussion to comment upon the potential implications of your findings for practice.

Abstract
-Please briefly describe your search strategy and state how many studies were included

Methods
-Please state your search strategy in Boolean Format

Results
-Please avoid any discussion in this section eg p9 L55 - stick to objective results.
-consider combining Tables 1-4
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
I own four shares in AstraZeneca PLC I have received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, Sanofi.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal